4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic Acid-d5

Request For Quotation
4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic Acid-d5 Basic information
Product Name:4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic Acid-d5
Synonyms:4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic Acid-d5
CAS:
MF:C19H23D5O2
MW:293.45522889
EINECS:
Product Categories:
Mol File:Mol File
4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic Acid-d5 Structure
4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic Acid-d5 Chemical Properties
solubility DMF: 50 mg/ml
DMSO: 50 mg/ml
Ethanol: 50 mg/mlPBS (pH 7.2): 0.1 mg/ml
Safety Information
MSDS Information
4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic Acid-d5 Usage And Synthesis
Description4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic acid-d5 is intended for use as an internal standard for the quantification of 4(Z),7(Z),10(Z),13(Z),16(Z)-nonadecapentaenoic acid by GC- or LC-MS. 4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic acid (19:5 n-3) is an impurity generated during the synthesis of docosahexaenoic acid-d5 (Item No. 10005057). While the physiological properties of this compound are not known, dietary intake of n-3 long chain polyunsaturated fatty acids provides potential health benefits.1WARNING This product is not for human or veterinary use.
References[1] V C VAUGHAN  P A L  M R Hassing. Marine polyunsaturated fatty acids and cancer therapy[J]. British Journal of Cancer, 2013, 108 3: 486-492. DOI: 10.1038/bjc.2012.586
4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic Acid-d5 Preparation Products And Raw materials
Tag:4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic Acid-d5 Related Product Information
4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic Acid 4(Z),7(Z)-Decadienoic Acid-d5 4(Z),7(Z),10(Z),13(Z)-Hexadecatetraenoic Acid-d5 (±)-10-hydroxy-12(Z)-Octadecenoic Acid-d5 4(Z),7(Z),10(Z)-Tridecatrienoic Acid-d5